Foundation and core beliefs
Our Ambition
Neurological disorders are devastating and complex conditions with limited treatment options. By applying our innovative platform technology, we seek to create novel solutions for life-changing therapeutics to patients in medical need.
Our Foundation
Our employees are the foundation for the growth and progress of Contera Pharma. We are agile, ambitious and committed to make a difference for patients. We seek synergies in partnerships and collaborations to accomplish our goals.
Our Science
We are focused on creating a de-risked portfolio of projects aimed at human validated targets. Our scientific capacity and pharma knowledge base serve as strong levers for unraveling both the molecular mechanisms as well as solving the pharmacological challenges in disease.
Recent News
September 27, 2022
Vernalis Research, a fully owned subsidiary of HitGen Inc., and Contera Pharma A/S announce a strategic collaboration in the field of RNA-targeting small molecules in neurology
Cambridge UK, and Copenhagen, Denmark, 27 September 2022 – Vernalis Research (“Vernalis”), a fully owned subsidiary of HitGen Inc., and Contera Pharma A/S (“Contera”)…
Read more
September 08, 2022
Contera Pharma signs agreement with BDD Pharma for development of a novel tablet formulation to treat nocturnal symptoms and morning akinesia in Parkinson´s disease
Contera Pharma, a biotech company developing innovative therapies to treat neurological disorders, has entered into collaboration with BDD Pharma, a drug delivery…
Read more
Contact us
Contera Pharma Headquarter
Contera Pharma A/S
Venlighedsvej 4
2970 Hørsholm
Denmark
Thomas Sager, CEO
info@conterapharma.com
